
Annual report 2024
added 04-25-2026
Nano-X Imaging Ltd. Net Income 2011-2026 | NNOX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Nano-X Imaging Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -53.5 M | -60.8 M | -113 M | -61.8 M | -43.8 M | -22.6 M | -1.91 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.91 M | -113 M | -51.1 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.26 | 4.63 % | $ 1.37 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 13.03 | 1.8 % | $ 1.76 B | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
LivaNova PLC
LIVN
|
-242 M | $ 63.81 | -0.61 % | $ 3.48 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
LENSAR
LNSR
|
-34.3 M | $ 5.1 | 0.2 % | $ 61 M | ||
|
Pulmonx Corporation
LUNG
|
-54 M | $ 1.27 | 0.39 % | $ 51.7 M | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
247 M | $ 190.15 | 0.31 % | $ 13.4 B | ||
|
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.63 | 0.86 % | $ 39.2 M | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.27 | 1.24 % | $ 122 M | ||
|
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.52 | -2.21 % | $ 326 M | ||
|
Globus Medical
GMED
|
538 M | $ 93.82 | -1.11 % | $ 12.7 B | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.5 | 1.21 % | $ 6.93 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
7.54 M | $ 26.45 | -0.11 % | $ 224 M | ||
|
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | ||
|
Stryker Corporation
SYK
|
849 M | $ 328.51 | 0.31 % | $ 126 B | ||
|
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | ||
|
Tactile Systems Technology
TCMD
|
19.1 M | $ 24.95 | -0.48 % | $ 571 M | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
TransMedics Group
TMDX
|
190 M | $ 109.0 | -1.74 % | $ 3.71 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 16.3 | 0.65 % | $ 382 M | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 5.38 | 0.94 % | $ 1.14 B | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Varex Imaging Corporation
VREX
|
-70.3 M | $ 12.49 | -0.32 % | $ 517 M | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 10.99 | 1.38 % | $ 394 M | ||
|
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.09 | 2.83 % | $ 18.5 M | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 39.54 | 3.13 % | $ 1.23 B | ||
|
Inspire Medical Systems
INSP
|
145 M | $ 55.85 | -0.82 % | $ 1.64 B | ||
|
Integer Holdings Corporation
ITGR
|
103 M | $ 84.93 | -1.27 % | $ 2.95 B | ||
|
PAVmed
PAVM
|
401 K | $ 8.81 | -2.11 % | $ 5.91 M | ||
|
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 83.67 | -0.57 % | $ 48.9 B |